Use of glucagon-like peptide-1 receptor agonists in people with history of acute pancreatitis: TriNetX analysis
Authors' conclusion
Based on our findings, we conclude that GLP-1RAs may be safely used in subjects with a history of acute pancreatitis. While our analysis showed that there was a significantly lower risk of AP recurrence in subjects on GLP-1compared to DPP-IV inhibitors and SGLT2 inhibitors, as this is a retrospective analysis we suggest that these findings need to be confirmed in prospective studies.
Study context
- Population
- Adults with a history of AP and T2D; PS matching in cohorts with and without risk factors for AP
- Participants
- 672,069 adults
- Exposure
- GLP-1RAs vs SGLT2i vs DPP-4i
- Outcome
- Recurrence of AP
Methodological detailsTriNetX platform, propensity score matching
- TriNetX platform
- Propensity score matching
Main finding
As reported in the abstract
AP recurrence · 1 year
Risk reduction
−0.071
95 % CI 0.085 to −0.057P < 0.001
Between GLP-1RAs and SGLT2i
Risk reduction
−0.064
95 % CI 0.080 to −0.048P < 0.001
Between GLP-1RAs and DPP-4i
Observational data: associations, not effects.
Further findings
| Outcome | Risk difference |
|---|---|
| AP recurrence · 5th yearGLP-1RAs vs SGLT2i | −0.086 |
| AP recurrence · 5th yearGLP-1RAs vs DPP-4i | −0.094 |
AP recurrence · 5th year
- GLP-1RAs consistently showed lower risk of AP recurrence vs SGLT2i and DPP-4i over 1 to 5 years
Original publication
Use of glucagon-like peptide-1 receptor agonists in people with history of acute pancreatitis: TriNetX analysis. Diabetes Metab. Published 17 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →